

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): KOSTENUIK et al.

RECEIVED

OCT 24 2002

TECH CENTER 1600/2900

Serial No.: 09/843,221

Group Art Unit No.: 1646

Filed: April 26, 2001

Examiner: Lazar Wesley

For: MODULATORS OF RECEPTORS FOR
PARATHYROID HORMONE AND PARATHYROID
HORMONE-RELATED PROTEIN

Docket No.: A-665B

HP

INFORMATION DISCLOSURE STATEMENT

BEFORE

**MAILING DATE OF EITHER A FINAL ACTION OR NOTICE
OF ALLOWANCE (37 CFR 1.97(c))**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

As a means of complying with the duty of disclosure, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form and provide a copy of each of the listed references for consideration by the Examiner.

This Information Disclosure Statement is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,
whichever occurs first.

STATEMENT OR FEE

Accompanying this transmittal is:

A a statement as specified in 37 CFR 1.97(e):

EXPRESS MAIL CERTIFICATE

Express Mail mail labeling number: EL360691880US

Date of Deposit:

Oct. 18, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

Lynne Buckbaum
Printed Name

Lynne Buckbaum
Signature

STATEMENT

I, the person(s) signing below state:

that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 CFR 1.97(e)(1).

OR

that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 CFR 1.97(e)(2).

OR

B. the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under § 1.97(c). (\$180.00).


Applicants request consideration of this information and passage of the application to issue.

FEE PAYMENT

Please charge Deposit Account No. 01-0519 in the amount of \$180.00 (37 CFR 1.97(c)). An original and one copy are enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519.

Respectfully submitted,



Robert B. Winter
Attorney/Agent for Applicant(s)
Registration No.: 34,458
Phone: (805) 447-2425
Date: October 18, 2002

Please send all future correspondence to:
US Patent Operations/RBW
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799